METABOLIC DISORDERS
Denosumab reduces risk of fractures in post-menopausal women
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.7868 women with osteoporosis, having a bone mineral density T score of less than -2.5 but no less than -4.0, were randomized to receive either injection with denosumab or an injection with placebo. Denosumab has been proposed to decrease bone resorption and thus improve bone mineral density in those patients with osteoporosis. This study aimed to assess the efficacy of denosumab injection as a treatment for osteoporosis, measured by occurrence of new vertebral fractures. The results from this study indicated that at 3 years the denosumab injections produced a reduction in new vertebral fractures compared to the placebo group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
